López MM

Language: Spanish
References: 10
Page: 84-87
PDF size: 51.52 Kb.

ABSTRACT

Percutaneous coronary interventions have been growing rapidly in recent years for their favorable outcome. Coronary artery disease, however, is caused by a diffuse atherosclerotic process involving the whole coronary artery tree and commonly other vascular territories. In recent years, evidence has accumulated that several classes of secondary preventive drugs are clinically effective. The statins are the cornerstone for lipid-lowering therapy and reduce morbidity and mortality in patients with ACS and treated with interventional cardiology. The highest risk of a recurrent event in patients with acute coronary syndromes (ACS) occurs in the first month, with the rates of reported events ranging from 10-25%. More recent data from several trials show that statin therapy can reduce cardiovascular risk in unstable disease. In the MIRACL trial, early initiation of atorvastatin after an episode of unstable angina or non-Q-MI reduced events along the ensuing 16 weeks. The Third Report of the Expert Panel Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) recommends that lipid lowering drug therapy be initiated at hospital discharge in patients with acute coronary syndromes and patients treated with percutaneous coronary interventions.

REFERENCES

1. Maron DJ, Fazio S, Linton MF: Current perspective on statins. Circulation 2000; 101: 207-213.

2. Aronow HD, Topol EJ, Roe MT, Houhtaling PL, Wolski KE, Lincoff AM, et al: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: and observational study. Lancet 2001; 357: 1063-68.

3. EUROASPIRE. A European Society of Cardiology survey of secondary coronary heart disease: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; results from EUROASPIRE II Eur Heart J 2001; 22: 554-7.

4. Danchin N, Grenier O, Ferrieres J, Cantent C, Cambou J-P: Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from nationwide French PREVENIR survey. Heart 2002; 88: 159-162.

5. Hunninghake D: Postdischarge lipid management of coronary artery disease patients according to the new national cholesterol education program guidelines. Am J Cardiol 2001; 88(Suppl): 37K-41K.

6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001; 285: 2486-2497.

7. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.

8. The Long term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.

9. The MIRACL Study Investigators: Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA 2001; 285: 1711-17188.

10. Walter DH, Fichtlscherer S, Britten MB, Fassbender S, Auch-Schwelk W, Schachinger V, Zeiher AM: Initiation of statin therapy immediately after stent implantation: profound benefit in patients with acute coronary syndromes. Circulation 2000; 102: II-435 Abstract 2119.